Search

EHA policy on double awarding

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.

EHA policy on double awarding

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.

Hematology Tutorial in Sri Lanka updates expertise on myeloid malignancies and MDS of local hematologists

Apr 17 2019 Posted in Tutorial reports

After a successful first edition in 2017, EHA and the Sri Lanka College of Haematologists (SLCH) organized its second two-day tutorial together in February in Colombo. The tutorial aimed to update the expertise of local hematologists from all levels.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Session information—May 15, 2025

Topic'Optimizing vaccination strategies for chemotherapy patients: Bridging gaps in preventive care. '

Speaker detailsVerena PetzerSince February 2025, Dr Verena Petzer has been a specialist in internal medicine for hematology and oncology at the Medical University of Innsbruck in Austria.

Highlights from the SWG

Events
The ERIC International Preceptorship, Realizing Precision Medicine in CLL: Why and How
Stresa, Italy
November 17–18, 2023
PublicationsRecent ERIC publications include:

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia
Other malignancies in the history of CLL: an international multicenter study conducted…

Board

The EHA Board is the governing body of the association and deals with issues of policy. The Board sets the goals and objectives of the association in conformity with the EHA's statutes.

Joint EHA and national society membership

Enjoy the best of both worlds—and save money—by combining an EHA membership with membership of your national hematology society. This special type of membership package is the result of our constructive collaborations with a range of national hematology societies.